Early carvedilol for heart failure shock
Part of Heart & circulation clinical trials.
This trial tests whether starting the heart failure medication carvedilol early, along with standard monitoring, can help people in cardiogenic shock (when the heart can't pump enough blood) due to a weak heart muscle. It aims to see if earlier treatment improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older, with no upper age limit.
- You have cardiogenic shock (your heart isn't pumping enough blood) and need care in an intensive care unit (ICU).
- You can take oral medication (pills by mouth).
- You are willing and able to give written informed consent, or have someone who can decide for you.
- You do not already have a mechanical heart pump or device for support.
- You have not had a recent heart attack (acute coronary syndrome) and do not have severe valve disease needing urgent surgery.
- You are not allergic to beta-blockers like carvedilol, and you have no asthma or bronchospasm history.
- You do not have a very slow heart rate, certain heart block problems, or sick sinus syndrome.
- You are not pregnant, within 30 days after childbirth, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a special pressure-monitoring tube in the heart’s main artery (a pulmonary artery catheter) helps people who are in cardiogenic shock from weak heart pumping. If you qualify, the goal is to improve how doctors monitor and treat this dangerous, fast-moving condition.
This study is testing a device called an intra-aortic balloon pump (a small balloon placed in your heart's main artery to help it pump) for people in the early stages of cardiogenic shock, a condition where the heart can't pump enough blood. The goal is to see if adding this supportive device early on improves outcomes for patients with heart attacks or other heart problems.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
This early study looks at how well the heart is pumping in people with cardiogenic shock, using measurements taken during a right-heart catheter (a small pressure-monitoring test). It may help doctors better assess heart function and guide next-step treatments like LVAD, heart transplant, or valve surgery.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.